文献速递免疫规划

使用ENABL®佐剂增强腺病毒载体口蹄疫病毒A型亚单位疫苗的效力

Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.
PubMed 文献 · Vaccine · 2018-01-20

在两项牛(steer)攻毒效力研究中评估了含脂质/聚合物佐剂的FMD重组亚单位疫苗。AdtA24+ENABL®组较无佐剂高剂量组在14 dpv时病毒中和抗体滴度显著更高、临床反应改善;同剂量AdtA24+ENABL®在7或14 dpv攻毒后防止所有牛出现临床口蹄疫,并提供90%抗病毒血症保护。

要点

  • AdtA24+ENABL®在14 dpv时病毒中和抗体滴度显著高于无佐剂高剂量组。
  • 同剂量AdtA24+ENABL®在7或14 dpv攻毒后防止所有牛临床口蹄疫,抗病毒血症保护90%。
  • 接种牛在攻毒前未产生FMDV非结构蛋白抗体,具备DIVA能力。

核心结论

  • AdtA24+ENABL®佐剂降低了保护剂量,并在接种牛7或14 dpv暴露于强毒FMDV后防止临床口蹄疫。

研究设计与样本

  • 两项牛(steer)疫苗效力攻毒研究:疫苗活性成分为复制缺陷型人腺病毒5型载体编码FMDV A24/Cruzeiro/BRA/55衣壳(AdtA24)。
  • 第一项研究比较AdtA24+ENABL®佐剂与四倍剂量无佐剂AdtA24。
  • 第二项研究使用与第一项研究相同剂量的AdtA24+ENABL®,在7或14 dpv进行FMDV A24/Cruzeiro/BRA/55攻毒。

主要发现

  • 第一项研究中,AdtA24+ENABL®组在14 dpv时病毒中和试验抗体滴度显著高于无佐剂活性成分组,临床反应改善。
  • 第二项研究中,AdtA24+ENABL®在7或14 dpv攻毒后防止所有牛出现临床口蹄疫,并提供90%抗病毒血症保护。
  • 接种牛攻毒后鼻样本FMDV滴度较未接种牛显著降低。
  • 两项研究中,AdtA24接种牛在攻毒前均未产生FMDV非结构蛋白抗体,表明具备区分感染与接种动物(DIVA)的能力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL® adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24 + ENABL® adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14 days post-vaccination (dpv) than steers vaccinated with the active ingredient alone. In the second study, vaccination with AdtA24 formulated in ENABL® at the same dose used in the first study, followed by FMDV A24/Cruzeiro/BRA/55 challenge on 7 or 14 dpv, prevented clinical FMD in all steers and conferred 90% protection against viremia. In addition, post-challenge FMDV titers in nasal samples from vaccinated steers compared to unvaccinated steers were significantly reduced. In both studies, none of the AdtA24 vaccinated steers developed antibodies to the FMDV non-structural proteins prior to challenge with FMDV, indicative of the capacity to differentiate infected from vaccinated animals (DIVA). These results demonstrate that administration of AdtA24 formulated in ENABL® adjuvant lowered the protective dose and prevented clinical FMD following exposure of vaccinated steers to virulent FMDV at 7 or 14 dpv.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Barrera J, Schutta C, Pisano M, et al. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine. Vaccine. 2018. PMID: 29358056. doi:10.1016/j.vaccine.2018.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。